Vor Biopharma Inc. (NYSE:VOR) Given Average Recommendation of “Buy” by Brokerages

Shares of Vor Biopharma Inc. (NYSE:VOR) have earned a consensus recommendation of “Buy” from the five ratings firms that are currently covering the stock, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have covered the stock in the last year is $13.50.

Several equities research analysts have issued reports on the stock. Wedbush reiterated an “outperform” rating and set a $11.00 target price on shares of Vor Biopharma in a research report on Thursday, March 21st. Oppenheimer reiterated an “outperform” rating and set a $15.00 target price (down from $17.00) on shares of Vor Biopharma in a research report on Thursday, March 21st. JMP Securities reissued a “market outperform” rating and set a $12.00 price target on shares of Vor Biopharma in a research note on Friday, March 22nd. Stifel Nicolaus decreased their price target on shares of Vor Biopharma from $15.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, March 21st. Finally, HC Wainwright reissued a “buy” rating and set a $17.50 price target on shares of Vor Biopharma in a research note on Thursday, March 21st.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Bank of America Corp DE increased its stake in shares of Vor Biopharma by 132.0% in the fourth quarter. Bank of America Corp DE now owns 3,942 shares of the company’s stock worth $26,000 after buying an additional 2,243 shares during the period. UBS Group AG purchased a new position in shares of Vor Biopharma in the fourth quarter worth $27,000. Boothbay Fund Management LLC increased its stake in shares of Vor Biopharma by 36.4% in the first quarter. Boothbay Fund Management LLC now owns 19,536 shares of the company’s stock worth $105,000 after buying an additional 5,216 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Vor Biopharma by 63.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 17,792 shares of the company’s stock worth $96,000 after buying an additional 6,917 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of Vor Biopharma by 28.2% in the second quarter. Renaissance Technologies LLC now owns 36,400 shares of the company’s stock worth $112,000 after buying an additional 8,000 shares during the period. 97.29% of the stock is owned by hedge funds and other institutional investors.

Vor Biopharma Price Performance

Shares of Vor Biopharma stock opened at $2.37 on Friday. Vor Biopharma has a 1 year low of $1.62 and a 1 year high of $5.70. The firm has a market cap of $161.56 million, a PE ratio of -1.35 and a beta of -0.38. The company has a 50 day simple moving average of $2.16 and a two-hundred day simple moving average of $2.14.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.